Skip to main content
Live
Main content

Isomorphic Labs raises $5B Series C co-led by Greenoaks and Sequoia

Andreessen Horowitz joins the oversubscribed round as the DeepMind spinout pushes its AI-designed drug candidates toward clinical trials.

Jaeden Schafer
Editor in Chief · · 4 min read
Isomorphic Labs raises $5B Series C co-led by Greenoaks and Sequoia

Isomorphic Labs has raised $5 billion in Series C funding, the AI drug design company announced on Tuesday. Greenoaks and Sequoia Capital co-led the oversubscribed round, and the London-based company says the money will help carry its AI-designed drug candidates toward clinical trials.

Andreessen Horowitz joined as a new investor alongside several other unnamed new backers, and Alphabet made what Isomorphic Labs described as continued significant investment. Existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participated. The company did not disclose a valuation; reports earlier this month said it was seeking roughly $50 billion.

“Discovering and developing new medicines is an optimization challenge of almost infinite scale”
— Neil Mehta, Founder and Managing Partner of Greenoaks

The raise lands about six months after Isomorphic Labs closed a $2.1 billion Series B in May. It is also the company's first fundraise since founder and CEO Demis Hassabis left his post running Google DeepMind to focus on drug discovery, moving into a chairman role at the lab.

Key facts

  • 01Isomorphic Labs raised $5 billion in Series C funding, co-led by Greenoaks and Sequoia Capital.
  • 02Andreessen Horowitz joined as a new investor, alongside Alphabet, Thrive Capital, GV, CapitalG, MGX, Temasek and the UK Sovereign AI Fund.
  • 03The round follows a $2.1 billion Series B closed in May 2026, and no valuation was disclosed.
  • 04The company reports positive preclinical results in oncology and immunology, with programs moving toward clinical trials.
  • 05Funds will go to the IsoDDE drug design engine and new AI-first clinical development infrastructure.

Isomorphic Labs was spun out of DeepMind in 2021. Hassabis shared the Nobel Prize in chemistry with John Jumper for AlphaFold, and he now leads Isomorphic alongside President Max Jaderberg. The company is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.

“Isomorphic Labs is building foundational technology for the future of medicine”
— Konstantine Buhler, Partner at Sequoia Capital

The company laid out several uses for the new capital. It plans to mature IsoDDE, its in-house drug design engine, and push it into new areas of biology, build a partner ecosystem around mechanistic disease biology, and stand up global infrastructure for AI-led bioengineering.

Isomorphic Labs also plans to build AI-first translational and clinical development infrastructure as its candidates advance. Its pipeline spans internal and partnered candidates across multiple modalities, and the company reports positive preclinical results in oncology and immunology, both in its own programs and with partners, which it says sets the stage for clinical entry.

“Every week we are making repeatable scientific advancements enabled by our models”
— Max Jaderberg, President of Isomorphic Labs

On the commercial side, Isomorphic Labs has existing drug discovery deals with Eli Lilly, Novartis and Johnson & Johnson. The funding announcement did not name new partners or individual drug programs.

The investor statements framed the round as a bet on the underlying platform rather than any single molecule. Greenoaks founder Neil Mehta pointed to the scale of the optimization problem in medicine, while Sequoia partner Konstantine Buhler described the company's work as foundational technology.

Related · from this week
Isomorphic Labs in talks to raise $5B at a $50B valuation
Jaeden Schafer · 4 min read →

Isomorphic Labs said its programs are moving toward clinical trials, but it gave no date for when its first AI-designed candidate will enter human testing.

ShareXLinkedInEmail
AI Box

Every AI model. One chat.

The latest models from ChatGPT, Claude, Gemini, Sora, ElevenLabs — 80+ models in a single chat. Compare answers side by side. Pick the best one every time.

  • ChatGPT, Claude, Gemini, Grok, DeepSeek — in one chat
  • Generate images & video with Sora, Veo, Ideogram
  • Compare any two models side by side
  • From $8.99/mo · 80+ models, all included
Try AI Boxaibox.ai
Trusted by 3,000+ teams
Got a tip?

Working on something we should cover, or seeing a story we missed? Send leads, documents, or feedback to hello@aichatdaily.com. For sensitive tips, see our secure tips page for Signal and PGP options.

Spotted an error? Email hello@aichatdaily.com with the URL and the issue, or read our full corrections policy.

AI Box Daily briefingFree · Daily · No fluff

Stay ahead of everyone in AI.

The tightly edited AI news email engineers, founders, and investors actually open. One email. Every weekday. Five minutes to finish.

Loved by 10,000+ AI professionals
Free forever. Unsubscribe with one click.

The briefing read inside teams at

Keep reading

More from Business

Google logo
Business

Isomorphic Labs in talks to raise $5B at a $50B valuation

The Alphabet-backed drug discovery company raised $2.1B in May and has yet to test one of its own drug candidates in humans.

Jaeden Schafer4 min read
Google logo
News

Demis Hassabis now expects AGI within two to three years

The Google DeepMind CEO pulls his forecast forward again, says he sees no insurmountable obstacles to curing cancer with AI, and warns against early regulation.

Jaeden Schafer3 min read
Listen Labs walks away from $1.5B Menlo round for Salesforce talks
Business

Listen Labs walks away from $1.5B Menlo round for Salesforce talks

The AI market research startup ditched a signed term sheet as Salesforce weighs a $2B acquisition at 67x revenue.

Jaeden Schafer4 min read